



Director/PDMR Shareholding

December 8, 2021

RNS Number : 9024U
Renalytix PLC
08 December 2021

Renalytix plc
("Renalytix" or the "Company")

Director/PDMR Dealing

New York, 8 December 2021 - Renalytix (LSE: RENX) announces that it has been advised of the purchase by James McCullough, the Company's Chief Executive Officer, of 950 American Depositary Shares ("ADS") in open market purchases using personal funds, each representing two ordinary shares of £0.0025 each in the capital of the Company ("Ordinary Shares"), at an aggregate price of \$15.04 per ADS.

Following completion of the purchase, James McCullough is interested in 2,742,010 Ordinary Shares representing 3.8% of the current issued share capital of the Company.

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)
Alex Price / Nicholas Moore

Tel: 020 7710 7600

Investec Bank plc (Joint Broker)
Gary Clarence / Daniel Adams

Tel: 020 7597 4000

Walbrook PR Limited
Paul McManus / Lianne Applegarth

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303

About KidneyIntelX

KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for

kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

The information contained in this notification is disclosed in accordance with the requirements of MAR.

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name	James McCullough	
2	Reason for the notification		
a)	Position/status	Chief Executive Officer	
b)	Initial notification /Amendment	Initial Notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Renalytix plc	
b)	Legal Entity Identifier	213800NTOH3FK3WER551	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	ADS', each ADS representing two Ordinary Shares of £0.0025 each.	
	Identification code	US75973T1016	
b)	Nature of the transaction	Purchase of ADS'	
c)	Currency	US Dollar	
d)	Price(s) and volume(s)	Price(s)	Volume(s)

		\$15.05	100 ADS (representing 200 Ordinary Shares)
		\$14.86	100 ADS (representing 200 Ordinary Shares)
		\$15.00	250 ADS (representing 500 Ordinary Shares)
		\$15.10	500 ADS (representing 1000 Ordinary Shares)
e)	Aggregated information - Aggregated volume - Price - Aggregated total	950 ADS (representing 1900 Ordinary Shares) \$15.04 \$14,291.00	
f)	Date of the transaction	8 December 2021	
g)	Place of the transaction	Nasdaq Stock Exchange	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHEAAAXESDFFAA